2021 Asia‐Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout. (20th December 2021)
- Record Type:
- Journal Article
- Title:
- 2021 Asia‐Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout. (20th December 2021)
- Main Title:
- 2021 Asia‐Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout
- Authors:
- Lorenzo, Jose Paulo P.
Sollano, Ma. Hanna Monica Z.
Salido, Evelyn O.
Li‐Yu, Julie
Tankeh‐Torres, Sandra A.
Wulansari Manuaba, Ida Ayu Ratih
Rahman, Md Mujibur
Paul, Binoy J.
Mok, Mo Yin
De Silva, Monika
Padhan, Prasanta
Lim, Ai Lee
Marcial, Melvin
Vicera, Jennifer Jeanne
Haq, Syed Atiqul
Salman, Sami
Liyanage, Chiranthi K.
Keen, Helen I.
Yew Kuang, Cheng
Wei, James Cheng‐Chung
Hellmi, Rakhma Yanti
Chan, Charlie E.
Louthrenoo, Worawit - Abstract:
- Abstract: Background: Gout is the most prevalent inflammatory arthritis in the Asia‐Pacific region and worldwide. This clinical practice guideline (CPG) aims to provide recommendations based on systematically obtained evidence and values and preferences tailored to the unique needs of patients with gout and hyperuricemia in Asia, Australasia, and the Middle East. The target users of these guidelines are general practitioners and specialists, including rheumatologists, in these regions. Methods: Relevant clinical questions were formulated by the Steering Committee. Systematic reviews of evidence were done, and certainty of evidence was assessed using Grading of Recommendations Assessment, Development and Evaluation methodology. A multi‐sectoral consensus panel formulated the final recommendations. Results: The Asia‐Pacific League of Associations for Rheumatology Task Force developed this CPG for treatment of gout with 3 overarching principles and 22 recommendation statements that covered the treatment of asymptomatic hyperuricemia (2 statements), treatment of acute gout (4 statements), prophylaxis against gout flare when initiating urate‐lowering therapy (3 statements), urate‐lowering therapy (3 statements), treatment of chronic tophaceous gout (2 statements), treatment of complicated gout and non‐responders (2 statements), treatment of gout with moderate to severe renal impairment (1 statement), and non‐pharmacologic interventions (5 statements). Conclusion: RecommendationsAbstract: Background: Gout is the most prevalent inflammatory arthritis in the Asia‐Pacific region and worldwide. This clinical practice guideline (CPG) aims to provide recommendations based on systematically obtained evidence and values and preferences tailored to the unique needs of patients with gout and hyperuricemia in Asia, Australasia, and the Middle East. The target users of these guidelines are general practitioners and specialists, including rheumatologists, in these regions. Methods: Relevant clinical questions were formulated by the Steering Committee. Systematic reviews of evidence were done, and certainty of evidence was assessed using Grading of Recommendations Assessment, Development and Evaluation methodology. A multi‐sectoral consensus panel formulated the final recommendations. Results: The Asia‐Pacific League of Associations for Rheumatology Task Force developed this CPG for treatment of gout with 3 overarching principles and 22 recommendation statements that covered the treatment of asymptomatic hyperuricemia (2 statements), treatment of acute gout (4 statements), prophylaxis against gout flare when initiating urate‐lowering therapy (3 statements), urate‐lowering therapy (3 statements), treatment of chronic tophaceous gout (2 statements), treatment of complicated gout and non‐responders (2 statements), treatment of gout with moderate to severe renal impairment (1 statement), and non‐pharmacologic interventions (5 statements). Conclusion: Recommendations for clinically relevant scenarios in the management of gout were formulated to guide physicians in administering individualized care. … (more)
- Is Part Of:
- International journal of rheumatic diseases. Volume 25:Number 1(2022)
- Journal:
- International journal of rheumatic diseases
- Issue:
- Volume 25:Number 1(2022)
- Issue Display:
- Volume 25, Issue 1 (2022)
- Year:
- 2022
- Volume:
- 25
- Issue:
- 1
- Issue Sort Value:
- 2022-0025-0001-0000
- Page Start:
- 7
- Page End:
- 20
- Publication Date:
- 2021-12-20
- Subjects:
- acute gout -- chronic tophaceous gout -- clinical practice guidelines -- gout -- non‐pharmacologic -- prophylaxis -- urate‐lowering therapy
Rheumatology -- Periodicals
Rheumatology -- Asia -- Periodicals
Rheumatology -- Pacific Area -- Periodicals
Rheumatic Diseases -- Periodicals
Connective Tissue Diseases -- Periodicals
Immune System Diseases -- Periodicals
616.723 - Journal URLs:
- http://ejournals.ebsco.com/direct.asp?JournalID=715072 ↗
http://www.blackwell-synergy.com/loi/ijrd ↗
http://www.blackwellpublishing.com/aims.asp?ref=1756-1841&site=1 ↗
http://www3.interscience.wiley.com/journal/120118343/grouphome/home.html ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1756-185X ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/1756-185X.14266 ↗
- Languages:
- English
- ISSNs:
- 1756-1841
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.538180
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20548.xml